Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Ortho Regenerative Technologies Inc. (C:ORTH)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ORTH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Apr 06, 2021 07:15 ET
Ortho Regenerative Technologies Announces Submission of Investigational New Drug Application for ORTHO-R
Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021 MONTRÉAL, April 6, 2021 /CNW/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho RTI" or the "Company"), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today announced that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for the initiation of a Phase I/II clinical trial of ORTHO-R in rotator cuff tear repair.
Read full article
Mar 31, 2021 07:00 ET
Ortho Regenerative Technologies Secures DTC Eligibility for the Trading of Its Shares On the US OTCQB Market
MONTRÉAL, March 31, 2021 /CNW/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) ("Ortho RTI" or the "Company"), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.  
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.18
--
--
Price to Sales - TTM
--
14.13
14.28
Price to Book - most recent quarter
--
4.96
3.96
Price to Cash Flow per share - TTM
--
17.90
17.61
Price to Free Cash Flow per share - TTM
--
31.04
31.57
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Apr 30, 202116,23114,476
Apr 15, 20211,755-2,247
Mar 31, 20214,002-17,776
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Ortho Regenerative Technologies Inc is a Canada-based biotechnology company. The Company is developing a platform for the repair of tears to soft tissues in joints, and for articular cartilage repair, to restore healthy joint motion and prevent or delay osteoarthritis. The Company's initial focus is in creating new treatments for tears to the meniscus in the knee and the shoulder cuff. The Company's biopolymer has been designed for the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.

See business summary

 

Twitter

Search (past week) for $ORTH.CA

  • No tweets found